Vascular tone is tightly regulated by endothelium-derived factors. These include relaxing factors (EDRFs) such as nitric oxide (NO), hyperpolarizing factors (EDHFs), and contracting factors (EDCFs). Although EDHF is a prominent vasodilator, particularly in smaller arteries, little attention has been paid to the potential role of EDHF responses in diabetes. EDHF signaling may involve various factors, including several diŠusible factors and non-diŠusible factors (e.g., gap junctions). It has been demonstrated that the alterations in EDHF relaxation seen in mesenteric arteries from diabetic rats may be attributable to an increase in phosphodiesterase 3 (PDE3) activity, leading to a reduction in the action of adenosine 3′ ,5′ -cyclic monophosphate (cAMP), and consequently the activity of protein kinase A (PKA) is decreased in such arteries. Moreover, it has been suggested that the imbalance between EDRFs and EDCFs is present in mesenteric arteries from type 2 diabetic rats and the EDHF relaxation can be partly reversed by suppression of EDCF signaling. Indeed, chronic treatment with metformin, eicosapentaenoic acid, or thromboxane synthase inhibitor can reduce EDCF signaling and normalize EDHF signaling in mesenteric arteries from type 2 diabetic rats. Although the improvement or restoration of EDHF responses has not been the direct subject of any pharmaceutical eŠort, increasing cAMP/PKA signaling (e.g., by inhibiting PDE3 activity) or reducing EDCFs signaling has potential as an interesting therapeutic target in diabetic vasculopathy.
(A) ACh-induced EDHF-type relaxations (in the presence of 100 mM L-NNA and 10 mM indomethacin) in mesenteric arteries from control (Wistar) and STZ-induced (Diabetic) rats. (B, C) EŠects of the gap junction inhibitor 18a-glycyrrhetinic acid (18a-GA, 100 mM) and the PDE inhibitor IBMX (20 mM) on the EDHF-type relaxations in mesenteric arteries from control (B) and diabetic (C) rats. (D) EŠects of speciˆc PDE inhibitors on EDHFtype relaxations in mesenteric arteries from diabetic rats. EDHF-type relaxations were enhanced by the selective PDE3 inhibitor (1 mM cilostamide) but not by the selective PDE4 inhibitor (10 mM Ro 20 1724 影響を与えることが知られている．PKA subunits ACh-induced muscarinic receptor stimulation leads to G protein activation and elevations in cytosolic Ca 2＋ . Then, activated G protein (including bg-subunits) and/or Ca 2＋ may also elevate cAMP levels via AC activation (although it is currently unknown which isozyme of AC is activated), thereby enhancing the electrical conductance of myoendothelial gap junctions. In the holoenzyme state, PKA exists in an inactive form. After an increase in cAMP, the regulatory subunits bind to cAMP, resulting in the dissociation of the holoenzyme into a regulatory dimmer and two catalytic monomers. The free C subunits can then phosphorylate various substrates. EDHF signaling may be enhanced by PKA-induced phosphorylation of gap junction component connexin or K ＋ channels. The reduced EDHF-type relaxation present in the diabetic state may be attributable to an increase in PDE3 activity, leading to a reduction in the action of cAMP, and the reduced PKA activity may be due to an imbalance between the expressions of PKA catalytic and regulatory subunits. Cilostazol (PDE3 inhibitor) improves EDHF-type relaxations in diabetic rats via an increase in cAMP/PKA signaling. AC, adenylyl cyclase; e -, electrical charge; G, G protein; M, muscarinic receptor; PKA, protein kinase A; SKCa/IKCa, small-/intermediate-conductance 
